Alport Syndrome clinical trials at UCLA
1 research study open to eligible people
open to eligible people ages 18 years and up
The AFFINITY Study is a phase 2, open-label, basket study to evaluate the efficacy and safety of atrasentan in patients with proteinuric glomerular disease who are at risk of progressive loss of renal function.
Glendale, California and other locations
Our lead scientists for Alport Syndrome research studies include Niloofar Nobakht.